Dave A Ricks (@DaveARicks) header
Dave A Ricks (@DaveARicks) profile picture

Chair & CEO @EliLillyandCo. Building on 150 years of advancing human health by delivering breakthrough medicines and expanding access worldwide.

Indianapolis, Indiana
Joined November 2022
Photo by Dave A Ricks (@DaveARicks)
Dave A Ricks retweeted
General Medicine has two announcements with @EliLillyandCo today: GLP-1 weight management on LillyDirect, and a memory care pathway for early Alzheimer’s evaluation. Both show what our store can do for a partner, in very different ways. Weight management is relatively straightforward. But follow-through depends on customers seeing all their options, knowing the price, and having a clinician who understands their whole health picture and goals. We do that. Memory care is complicated. Figuring out what testing someone has had, what they still need, and how it all fits together is hard. As a result, patients often wait years between their first symptoms and a diagnosis. That delay is particularly consequential for new therapies with a narrow window for treatment. We bring bloodwork, cognitive testing, imaging, and specialist review together, coordinated by a clinician who knows how to navigate the process. We’re working to solve one of the biggest bottlenecks in Alzheimer’s care, today. The same store works for both: transparent pricing, clear next steps, and a clinician who helps you get it done. That’s the promise of what we’re building @GeneralMedicine: it’s simple to get the healthcare you need, no matter how complicated it might be We’re excited to work with Lilly to bring both experiences to more people.
19
13
7
140
19,560
Proud to build in Pennsylvania and build in America! Governor your team is terrific and we are excited to get this hi-tech plant built, hire 850 Lehigh Valley residents and make medicine for the world. The innovative medicines from our labs are amazing but will only have impact when they reach the people who need them. That starts with building capacity here in America. Let’s go!!🇺🇸🇺🇸🇺🇸
Back in January, @DaveARicks and I announced @EliLillyandCo’s $3.5 billion expansion in Pennsylvania — the largest life sciences deal in our Commonwealth’s history. Today, just eleven months later, we came back to the Lehigh Valley to put shovels in the ground.   Our rapid progress on this project is proof that our work to reform our permitting process and speed up government is WORKING — and that Pennsylvania is open for business.   Thanks to that work, Lilly will be able to begin manufacturing their life-changing medicines sooner than expected, and thousands of Pennsylvanians will find a good-paying job here in Fogelsville as a result.   That’s GSD.
9
6
1
110
11,944
LIVE NOW: Less than a year ago, we announced @EliLillyandCo’s decision to invest $3.5 billion in PA, right here in the Lehigh Valley. This project is moving full speed ahead. Join CEO @DaveARicks and me as we break ground on this project. WATCH: nitter.cf/i/broadcasts/2mdrBOebe…
16
8
2
44
7,082
I think that would be amazing and I think it’s not likely. The map of biology is still largely a blank page and randomized human proof is the long pole in the tent. I am excited about the use of AI in our sector but progress will likely be steady and incremental.
“Cancer, Alzheimer’s, heart disease, mental illness - these will be relics of the past in, I think, less than a decade.” — Anthropic CEO @DarioAmodei What do you think, bio folks? Source: instagram.com/reel/DfkundEE2…
77
114
47
984
275,902
Thanks for surfacing. Macros plus resistance is the way.
This new tirzepatide study is eye-opening. 120 adults took the drug for 40 weeks, and half of them also lifted weights 3x a week. Both groups lost about 50 lbs. But when they tested strength, the two groups looked nothing alike. Here's the breakdown: (1/11)
13
29
3
452
100,215
Dave A Ricks retweeted
Presented at #ACR26: The WOMAC pain score and body weight decreased significantly more with retatrutide than with placebo in patients with painful knee osteoarthritis and obesity. Full results of the phase 3 TRIUMPH-4 and TRIUMPH-1-OA trials: nej.md/4A4V4OK @ACRheum
6
26
3
73
15,656
Convincingly negative result here. IL6 looks almost the same. Not often 2 of the most anticipated targets in CV go down at once. There will be lots of Monday morning quarterbacking these bets but it’s why we do the studies and they were reasoned bets, uncertain outcomes despite genetics and biomarkers with asymmetric value if positive. Drug development isn’t rocket science, its actually much harder. In the near term, beyond LDL optimization (looks like real benefit), Incretin therapy in obesity now the one big idea left on the board to reduce CVD death and disability at scale. Surmount MMO is coming! clinicaltrials.gov/study/NCT… Pelacarsen and Cardiovascular Outcomes in Patients with High Lipoprotein(a) | New England Journal of Medicine nejm.org/doi/full/10.1056/NE…
27
33
11
358
65,870
Obesity is the root disease for over 200 chronic diseases, it impacts more than 1 in 7 people on the planet and more options are needed. Science doing a good job here making the case for much more innovation in Obesity care. It’s still very early, yet we can see the impact that is possible. Lilly doing our part to lead on new mechanisms, more convenient, more durable and more accessible weight loss solutions for the world. Obesity management medications: The way forward | Science science.org/doi/10.1126/scie…
17
44
7
278
19,674
I’ll take that bet.
Agree 100% but unlikely it will come from the big bio companies
177
199
90
3,610
5,187,057
Proud of TEAM Lilly, we are executing well. While 2026 is setting up to be a year to remember I am even more excited about our future… - 4 Incretin projects in phase 3 now, raising the bar of what’s possible in weight loss, reducing side effect burden and radically expanding indications caused by obesity. We are building the tools to solve overweight and obesity, and hopefully the 200 terrible diseases it causes, at a global scale. -Rapidly expanding Cancer portfolio in B cell driven disease, Breast and Ovarian cancer as well as Lung and more. - Treating or preventing the worst neurodegenerative diseases we know - Unlocking the potential of one and done therapy for common diseases like lymphomas, wet AMD, childhood deafness and even something as common as high LDL cholesterol. The future of biomedical technology is going to amaze.
Today we announced third-quarter 2026 results. Every quarter is a chance to show what a medicine company can do for people: discover what's next, make it at scale, and get it to the people who need it. go.lilly.com/lkq1zh
15
25
5
300
26,980
In a head-to-head Phase 3 study in adults with type 2 diabetes, our investigational triple agonist delivered greater reductions in A1C and more than double the weight loss compared to an injectable GLP-1 at 80 weeks. Read more: go.lilly.com/ihqbej
14
13
12
64
9,815
Building more! New $5B API site in Virginia to make our next generation of cancer medicines. This site will make Monoclonal Antibodies and ADCs and is our first effort to have the entire process, from starting material to finished product, on one site. Thanks to Governor @SpanbergerForVA and Ambassador @jamiesongreer for your help to get us here and for joining our celebration today!
Today we broke ground at our second U.S. facility in two months as part of our ongoing investment in domestic manufacturing. We’re building the future home of next-gen cancer medicines in Goochland, VA, and bringing 650 high-wage jobs to the area. Read more go.lilly.com/x6ilni
7
9
2
144
17,266
Not good.
Your peptides may be coming fentanyl suppliers. Anhui Renchen Technology was indicted in 2023 for supplying the Sinaloa Cartel with fentanyl precursors. Their website currently sells semaglutide and melanotan II. Of roughly 200 Chinese firms TRM Labs tracked selling fentanyl precursors, at least 50 now sell peptides. The shipments enter the US in “master cartons” mislabelled as snack food, broken up by a domestic handler and mailed on. CBP has intercepted around 400 of those operations and seized over 130,000 vials in the past year. FDA records surfaced showing two deaths, one in July and one in September, reported after people injected untested black market retatrutide.
9
12
4
146
18,836
Dave A Ricks retweeted
Presented at #SleepEurope2026: In two phase 3 trials involving participants with OSA and obesity or overweight with or without type 2 diabetes, treatment with retatrutide was found to result in greater decreases in the apnea–hypopnea index than placebo. Full results of the TRIUMPH-1-OSA and TRIUMPH-2-OSA trials: nej.md/4BmAHOI @ESRS_Sleep
14
57
8
177
28,081
One month (or so) on @X , a platform unlike any other. Energy, speed, smarts and stupidity. -The best thing in BioX - Rapid and divergent takes on new clinical data, on balance usually right..wisdom of crowds -The worst thing on BioX - Shameless replies and reposts pumping your own book, praying for M&A about your favorite name, plane stalking…do people actually think this is how a real drug company or serious investor makes decisions? Maybe it just makes you feel like you have some agency, then ok.
111
55
72
758
184,899
Two souls are dead because they self administered something purporting to be the most powerful metabolic agent ever developed - without medical supervision, before the inventor has asked for approval and sourced from a Chinese “lab” seeking to make a quick buck. Peptide World - “Lilly made this up”.
45
56
9
511
118,116